Format

Send to

Choose Destination
BMC Cancer. 2019 Mar 4;19(1):198. doi: 10.1186/s12885-019-5413-y.

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.

Author information

1
Radiation Oncology Department, Centre François Baclesse, 3 avenue du Général Harris, F-14076, Caen, France. Paul.lesueur89@gmail.com.
2
Normandy university, University of Caen Basse Normandie, 14000, Caen, France. Paul.lesueur89@gmail.com.
3
Clinical Research Department Centre François Baclesse, Caen, France.
4
Medical Oncology Department, Centre François Baclesse, 14076, Caen, France.
5
Radiation Oncology Department, Centre François Baclesse, 3 avenue du Général Harris, F-14076, Caen, France.
6
Normandy university, University of Caen Basse Normandie, 14000, Caen, France.
7
Neurosurgery Department, CHU de Caen, Caen, France.
8
Genetic and oncology biology Department, Centre François Baclesse, Caen, France.
9
Radiology Department, Centre François Baclesse, Caen, France.
10
UNICAEN, INSERM, U1086 Anticipe, Normandie University, 14076, Caen, France.
11
IT department, Centre François Baclesse, F-14000, Caen, France.
12
Pharmacy, Centre François Baclesse, F-14000, Caen, France.
13
Northwest Data Center (CTD-CNO), Centre François Baclesse, F-14000, Caen, France.

Abstract

BACKGROUND:

Despite multimodality treatments including neurosurgery, radiotherapy and chemotherapy, glioblastoma (GBM) prognosis remains poor. GBM is classically considered as a radioresistant tumor, because of its high local recurrence rate, inside the irradiation field. The development of new radiosensitizer is crucial to improve the patient outcomes. Pre-clinical data showed that Poly (ADP-ribose) polymerase inhibitors (PARPi) could be considered as a promising class of radiosensitizer. The aim of this study is to evaluate Olaparib, a PARPi, as radiosensitizing agent, combined with the Stupp protocol, namely temozolomide (TMZ) and intensity modulated radiotherapy (IMRT) in first line treatment of partially or non-resected GBM.

METHODS:

The OLA-TMZ-RTE-01 study is a multicenter non-randomized phase I/IIa trial including unresectable or partially resectable GBM patients, from 18 to 70 years old. A two-step dose-escalation phase I design will first determine the recommended phase 2 dose (RP2D) of olaparib, delivered concomitantly with TMZ plus conventional irradiation for 6 weeks and as single agent for 4 weeks (radiotherapy period), and second, the RP2D of olaparib combined with adjuvant TMZ (maintenance period). Phase IIa will assess the 18-month overall survival (OS) of this combination. In both phase I and IIa separately considered, the progression-free survival, the objective response rate, the neurocognitive functions of patients, emotional disorders among caregivers, the survival without toxicity, degradation nor progression, the complications onset and the morphologic and functional MRI (magnetic resonance imaging) parameters will be also assessed as secondary objectives. Ancillary objectives will explore alteration of the DNA repair pathways on biopsy tumor, proton magnetic resonance spectroscopy parameters to differentiate tumor relapse and radionecrosis, and an expanded cognition evaluation. Up to 79 patients will be enrolled: 30 patients in the phase I and 49 patients in the phase IIa.

DISCUSSION:

Combining PARP inhibitors, such as olaparib, with radiotherapy and chemotherapy in GBM may improve survival outcomes, while sparing healthy tissue and preserving neurocognitive function, given the replication-dependent efficacy of olaparib, and the increased PARP expression in GBM as compared to non-neoplastic brain tissue. Ancillary studies will help to identify genetic biomarkers predictive of PARPi efficacy as radiosensitizer.

TRIAL REGISTRATION:

NCT03212742 , registered June, 7, 2017. Protocol version: Version 2.2 dated from 2017/08/18.

KEYWORDS:

Glioblastoma; Poly (ADP-ribose) polymerase (PARP); Radiosensitizer, olaparib; Radiotherapy

PMID:
30832617
PMCID:
PMC6399862
DOI:
10.1186/s12885-019-5413-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center